Testosterone deficiency is a cause of anemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease
This observational study assessed a) the association between testosterone levels and hemoglobin in nondialysed CKD Stages 1-5 ESA-naive male patients as well as the association between testosterone levels and ESA dose in ESA-treated males undergoing hemodialysis. CKD patients with lower testosterone values were 5.3 times more likely to be anemic. In patients undergoing HD, higher ESAs doses were associated with lower testosterone values. This observational data raises the possibility that restoring testosterone levels may enhance anemia management in CKD.
- Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials
- Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis.
- Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients